[go: up one dir, main page]

JO3343B1 - أحماض 5- أمينوتتراهيدروكوينولين-2- كربوكسيليك جديدة واستخدامها - Google Patents

أحماض 5- أمينوتتراهيدروكوينولين-2- كربوكسيليك جديدة واستخدامها

Info

Publication number
JO3343B1
JO3343B1 JOP/2013/0216A JOP20130216A JO3343B1 JO 3343 B1 JO3343 B1 JO 3343B1 JO P20130216 A JOP20130216 A JO P20130216A JO 3343 B1 JO3343 B1 JO 3343B1
Authority
JO
Jordan
Prior art keywords
carboxylic acids
novel5
aminotetrahydroquinoline
ofdiseases
prevention
Prior art date
Application number
JOP/2013/0216A
Other languages
English (en)
Inventor
Delbeck Martina
Terebesi Iidiko
Eva-Maria Becker Dr
Joerg Keldenich Dr
Frank Wunder Dr
Hanna Tinel Dr
Lang Dieter
Martin Rene
Hübsch Walter
Follmann Markus
Hahn Michael
Mittendorf Joachim
Stasch Johannes-Peter
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Application granted granted Critical
Publication of JO3343B1 publication Critical patent/JO3343B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

يتعلق الاختراع الحالي مع 5-amino-5,6,7,8-tetrahydroquinoline-2-carboxylic acids جديدة ، بعمليات (processes) لتحضيرها، باستخدامها لمعالجة و/أو منع أمراض، وباستخدامها لتحضير أدوية (medicaments) لمعالجة و/أو منع أمراض، بصفة خاصة لمعالجة و/أو منع اضطرابات القلب والأوعية الدموية.
JOP/2013/0216A 2012-07-20 2013-07-18 أحماض 5- أمينوتتراهيدروكوينولين-2- كربوكسيليك جديدة واستخدامها JO3343B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12177284 2012-07-20
EP13167967 2013-05-16

Publications (1)

Publication Number Publication Date
JO3343B1 true JO3343B1 (ar) 2019-03-13

Family

ID=48914233

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2013/0216A JO3343B1 (ar) 2012-07-20 2013-07-18 أحماض 5- أمينوتتراهيدروكوينولين-2- كربوكسيليك جديدة واستخدامها

Country Status (41)

Country Link
US (3) US8981104B2 (ar)
EP (1) EP2875003B1 (ar)
JP (1) JP6251259B2 (ar)
KR (1) KR102137517B1 (ar)
CN (1) CN104822661B (ar)
AR (1) AR091838A1 (ar)
AU (1) AU2013292046C1 (ar)
BR (1) BR112015001211B1 (ar)
CA (1) CA2879369C (ar)
CL (1) CL2015000120A1 (ar)
CO (1) CO7240369A2 (ar)
CR (1) CR20150020A (ar)
CY (1) CY1118588T1 (ar)
DK (1) DK2875003T3 (ar)
DO (1) DOP2015000012A (ar)
EA (1) EA028918B9 (ar)
EC (1) ECSP15001882A (ar)
ES (1) ES2616036T3 (ar)
GT (1) GT201500011A (ar)
HK (1) HK1209413A1 (ar)
HR (1) HRP20170185T1 (ar)
HU (1) HUE030540T2 (ar)
IL (1) IL236616B (ar)
JO (1) JO3343B1 (ar)
LT (1) LT2875003T (ar)
ME (1) ME02603B (ar)
MX (1) MX360863B (ar)
MY (1) MY172994A (ar)
NZ (1) NZ702977A (ar)
PE (1) PE20150350A1 (ar)
PH (1) PH12015500106B1 (ar)
PL (1) PL2875003T3 (ar)
PT (1) PT2875003T (ar)
RS (1) RS55651B1 (ar)
SG (2) SG11201408421TA (ar)
SI (1) SI2875003T1 (ar)
TN (1) TN2015000026A1 (ar)
TW (1) TWI598338B (ar)
UY (1) UY34918A (ar)
WO (1) WO2014012934A1 (ar)
ZA (1) ZA201409394B (ar)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE049976T2 (hu) 2005-12-28 2020-11-30 Vertex Pharma N-[2,4-bisz(1,1-dimetil-etil)-5-hidroxi-fenil]-1,4-dihidro-4-oxo-kinolin-3-karboxamid amorf alakjának gyógyászati kompozíciói
DE102011007272A1 (de) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
CN104245663B (zh) * 2012-04-16 2016-10-26 东亚荣养株式会社 二环化合物
LT2875003T (lt) * 2012-07-20 2017-02-27 Bayer Pharma Aktiengesellschaft Naujos 5-aminotetrahidrochinolin-2-karboksirūgštys ir jų panaudojimas
WO2014012935A1 (de) 2012-07-20 2014-01-23 Bayer Pharma Aktiengesellschaft Substituierte aminoindan- und aminotetralin-carbonsäuren und ihre verwendung
FR3000065A1 (fr) * 2012-12-21 2014-06-27 Univ Lille Ii Droit & Sante Composes bicycliques ayant une activite potentialisatrice de l'activite d'un antibiotique actif contre les mycobacteries-composition et produit pharmaceutiques comprenant de tels composes
AU2015330923B2 (en) 2014-10-07 2020-03-12 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
CA2984983A1 (en) 2015-05-06 2016-11-10 Bayer Pharma Aktiengesellschaft The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc)
WO2017013010A1 (de) 2015-07-23 2017-01-26 Bayer Pharma Aktiengesellschaft Stimulatoren und/oder aktivatoren der löslichen guanylatzyklase (sgc) in kombination mit einem inhibitor der neutralen endopeptidase (nep inhibitor) und/oder einem angiotensin aii-antagonisten und ihre verwendung
JPWO2018016611A1 (ja) * 2016-07-22 2019-05-09 トーアエイヨー株式会社 緑内障治療薬
CN109890379A (zh) 2016-10-11 2019-06-14 拜耳制药股份公司 包含sGC活化剂和盐皮质激素受体拮抗剂的组合产品
WO2018153899A1 (de) 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit stimulatoren und/oder aktivatoren der löslichen guanylatcyclase (sgc)
EP3700903A1 (de) 2017-10-24 2020-09-02 Bayer Aktiengesellschaft Substituierte imidazopyridinamide und ihre verwendung
WO2019081456A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT
EP3498298A1 (en) 2017-12-15 2019-06-19 Bayer AG The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi)
CN108218770A (zh) * 2018-02-28 2018-06-29 南京波普生物医药研发有限公司 2-氯-7,8-二氢-6h-喹啉-5-酮的制备方法
CN112055584A (zh) 2018-04-30 2020-12-08 拜耳公司 sGC活化剂和sGC刺激剂用于治疗认知障碍的用途
JOP20200287A1 (ar) 2018-05-15 2020-11-09 Bayer Ag بنزاميدات مستبدلة بـ 3،1- ثيازول-2- يل للمعالجة من أمراض مصاحبة لتحسس الألياف العصبية
US11508483B2 (en) 2018-05-30 2022-11-22 Adverio Pharma Gmbh Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group
US10905667B2 (en) 2018-07-24 2021-02-02 Bayer Pharma Aktiengesellschaft Orally administrable modified-release pharmaceutical dosage form
CN113330030A (zh) 2019-01-17 2021-08-31 拜耳公司 确定受试者是否适于用可溶性鸟苷酸环化酶(sGC)的激动剂治疗的方法
WO2020164008A1 (en) 2019-02-13 2020-08-20 Bayer Aktiengesellschaft Process for the preparation of porous microparticles
WO2020216669A1 (de) 2019-04-23 2020-10-29 Bayer Aktiengesellschaft Phenylsubstituierte imidazopyridinamide und ihre verwendung
AU2020268578A1 (en) 2019-05-07 2022-02-03 Bayer Aktiengesellschaft MASP inhibitory compounds and uses thereof
EP3822268A1 (en) 2019-11-15 2021-05-19 Bayer Aktiengesellschaft Substituted hydantoinamides as adamts7 antagonists
EP3822265A1 (en) 2019-11-15 2021-05-19 Bayer AG Substituted hydantoinamides as adamts7 antagonists
AU2021276066A1 (en) * 2020-05-20 2022-12-08 Bayer Aktiengesellschaft Process of preparing butyl-(5S)-5-({2-(4-(butoxycarbonyl)phenyl)ethyl}(2-(2-{(3-chloro-4'-(trifluoromethyl)(biphenyl)-4-yl)methoxy}phenyl)ethyl)amino)-5,6,7,8-tetrahydroquinoline-2-carboxylate
AR128147A1 (es) 2021-12-29 2024-03-27 Bayer Ag Procedimiento para la preparación del ácido (5s)-[2-(4-carboxifenil)etil][2-(2-[3-cloro-4’-(trifluorometil)bifenil-4-il]metoxifenil)etil]amino-5,6,7,8-tetrahidroquinolina-2-carboxílico y sus formas cristalinas para su uso como compuesto farmacéuticamente activo
CN118765199A (zh) * 2021-12-29 2024-10-11 拜耳股份公司 心肺病症的治疗
JP2025501302A (ja) 2021-12-29 2025-01-17 バイエル アクツィエンゲゼルシャフト 薬学的乾燥粉末吸入製剤
WO2023237577A1 (en) 2022-06-09 2023-12-14 Bayer Aktiengesellschaft Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8004002L (sv) 1980-05-29 1981-11-30 Arvidsson Folke Lars Erik Terapeutiskt anvendbara tetralinderivat
IL65501A (en) 1981-05-08 1986-04-29 Astra Laekemedel Ab 1-alkyl-2-aminotetralin derivatives,process for their preparation and pharmaceutical compositions containing them
DE3718317A1 (de) 1986-12-10 1988-06-16 Bayer Ag Substituierte basische 2-aminotetraline
DE3719924A1 (de) 1986-12-22 1988-06-30 Bayer Ag 8-substituierte 2-aminotetraline
CA2051399C (en) 1989-05-31 2003-12-30 Chiu-Hong Lin Therapeutically useful 2-aminotetralin derivatives
FR2659853A1 (fr) 1990-03-22 1991-09-27 Midy Spa Utilisation de derives 2-aminotetraliniques pour la preparation de medicaments destines a combattre les troubles de la motricite intestinale.
CA2180841C (en) 1994-01-10 2007-03-27 Sasson Cohen 1-aminoindan derivatives and compositions thereof
CA2333951C (en) 1998-06-01 2012-02-28 Ortho-Mcneil Pharmaceutical, Inc. Method for treating neurodegenerative disorders
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
GB9827467D0 (en) 1998-12-15 1999-02-10 Zeneca Ltd Chemical compounds
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10109861A1 (de) * 2001-03-01 2002-09-05 Bayer Ag Neuartige seitenkettenhalogenierte Aminodicarbonsäurederivate
DE10109859A1 (de) 2001-03-01 2002-09-05 Bayer Ag Neuartige Aminodicarbonsäurederivate
DE10109858A1 (de) * 2001-03-01 2002-09-05 Bayer Ag Neuartige halogensubstituierte Aminodicarbonsäurederivate
DE10110750A1 (de) * 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
US20050032873A1 (en) 2003-07-30 2005-02-10 Wyeth 3-Amino chroman and 2-amino tetralin derivatives
GB0318094D0 (en) * 2003-08-01 2003-09-03 Pfizer Ltd Novel combination
CA2600833A1 (en) 2005-03-30 2006-10-05 Merck & Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
DE102005047946A1 (de) * 2005-10-06 2007-05-03 Bayer Healthcare Ag Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Behandlung von akuten und chronischen Lungenkrankheiten
DE102005050377A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Heterocyclische Verbindungen und ihre Verwendung
DE102006031175A1 (de) * 2006-07-06 2008-01-10 Bayer Healthcare Ag Wässrige Arzneimittelformulierung von 4-[((4-Carboxybutyl)-(2[(4-phenethyl-benzyl)oxy]-phenethyl)amino)methyl]benzoesäur
US20090048295A1 (en) 2007-08-13 2009-02-19 Joseph Kent Barbay Substituted 5,6,7,8-tetrahydroquinoline derivatives, compositions, and methods of use thereof
CN101939053A (zh) 2007-09-06 2011-01-05 默沙东公司 可溶性的鸟苷酸环化酶活化剂
US8653099B2 (en) * 2008-08-19 2014-02-18 Janssen Pharmaceutica Cold menthol receptor antagonists
DE102010020553A1 (de) 2010-05-14 2011-11-17 Bayer Schering Pharma Aktiengesellschaft Substituierte 8-Alkoxy-2-aminotetralin-Derivate und ihre Verwendung
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
EP2687210A1 (de) 2010-06-25 2014-01-22 Bayer Intellectual Property GmbH Verwendung von Stimulatoren und Aktivatoren der löslichen Guanylatzyklase zur Behandlung von Sichelzellanämie und Konservierung von Blutersatzstoffen
CA2804470A1 (en) 2010-07-09 2012-01-12 Bayer Intellectual Property Gmbh Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
WO2012122340A1 (en) 2011-03-10 2012-09-13 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators
CN104245663B (zh) * 2012-04-16 2016-10-26 东亚荣养株式会社 二环化合物
LT2875003T (lt) * 2012-07-20 2017-02-27 Bayer Pharma Aktiengesellschaft Naujos 5-aminotetrahidrochinolin-2-karboksirūgštys ir jų panaudojimas
WO2014012935A1 (de) 2012-07-20 2014-01-23 Bayer Pharma Aktiengesellschaft Substituierte aminoindan- und aminotetralin-carbonsäuren und ihre verwendung

Also Published As

Publication number Publication date
HK1209413A1 (en) 2016-04-01
GT201500011A (es) 2017-10-09
MX360863B (es) 2018-11-09
CY1118588T1 (el) 2017-07-12
SI2875003T1 (sl) 2017-03-31
US9688636B2 (en) 2017-06-27
BR112015001211B1 (pt) 2020-12-15
CL2015000120A1 (es) 2015-06-26
AR091838A1 (es) 2015-03-04
ZA201409394B (en) 2016-07-27
PE20150350A1 (es) 2015-02-28
EA028918B9 (ru) 2018-07-31
DOP2015000012A (es) 2015-03-15
EA028918B1 (ru) 2018-01-31
KR102137517B1 (ko) 2020-07-24
US20150148376A1 (en) 2015-05-28
PH12015500106A1 (en) 2015-03-02
NZ702977A (en) 2017-10-27
ME02603B (me) 2017-06-20
SG11201408421TA (en) 2015-02-27
US10053428B2 (en) 2018-08-21
ES2616036T3 (es) 2017-06-09
SG10201700454PA (en) 2017-03-30
AU2013292046C1 (en) 2018-03-15
MX2015000739A (es) 2015-08-10
UY34918A (es) 2014-02-28
JP6251259B2 (ja) 2017-12-20
CN104822661A (zh) 2015-08-05
IL236616A0 (en) 2015-02-26
RS55651B1 (sr) 2017-06-30
EP2875003B1 (de) 2016-11-16
TWI598338B (zh) 2017-09-11
CA2879369A1 (en) 2014-01-23
EA201590251A1 (ru) 2015-07-30
HRP20170185T1 (hr) 2017-03-24
TW201408643A (zh) 2014-03-01
ECSP15001882A (es) 2015-09-30
AU2013292046B2 (en) 2017-12-14
WO2014012934A1 (de) 2014-01-23
JP2015522597A (ja) 2015-08-06
IL236616B (en) 2018-05-31
PL2875003T3 (pl) 2017-05-31
US20170260139A1 (en) 2017-09-14
TN2015000026A1 (en) 2016-06-29
PT2875003T (pt) 2017-02-16
MY172994A (en) 2019-12-18
LT2875003T (lt) 2017-02-27
CN104822661B (zh) 2017-05-31
US8981104B2 (en) 2015-03-17
CR20150020A (es) 2015-03-06
KR20150036084A (ko) 2015-04-07
CO7240369A2 (es) 2015-04-17
CA2879369C (en) 2020-09-22
HUE030540T2 (en) 2017-05-29
EP2875003A1 (de) 2015-05-27
BR112015001211A2 (pt) 2017-07-04
US20140031391A1 (en) 2014-01-30
AU2013292046A1 (en) 2015-02-19
PH12015500106B1 (en) 2020-01-31
DK2875003T3 (en) 2017-02-20

Similar Documents

Publication Publication Date Title
JO3343B1 (ar) أحماض 5- أمينوتتراهيدروكوينولين-2- كربوكسيليك جديدة واستخدامها
WO2015073587A3 (en) Synthetic membrane-receiver complexes
RS53893B1 (en) USE OF BIOTIN FOR MULTIPLE SCLEROSIS TREATMENT
AU355322S (en) Chair
PH12017500836A1 (en) Transdermal formulations
AU352197S (en) Hitch step
IN2015DN01524A (ar)
IN2014DN11078A (ar)
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
IN2014DN06738A (ar)
MX362070B (es) Polioles que contienen tanino, su producción y su uso.
AU352917S (en) Trailer jack
Wickelgren The education of character
PH12016501658A1 (en) Sialylated glycoprotein compositions and uses thereof
AU356192S (en) Shelving unit
MX2015000804A (es) Composiciones y metodos para tratar el sarcoma de ewing y otros trastornos relacionados con ews-fli1.
IN2014DN07191A (ar)
MY184721A (en) Use of odiparcil in the treatment of a mucopolysaccharidosis
MX2015009161A (es) Polioles, su preparación y su uso.
MX345908B (es) Sistema de energía comestible.
AU346989S (en) Coupling nut
UA80618U (en) Use of n-steroylethanolamine as radiomodifier
UA75621U (uk) Застосування капсул "фітовенол" як лікувально-профілактичного засобу з антитромботичною дією
CA146003S (en) Anti-wrinkle device
AU345696S (en) Textiles